There’s huge excitement over the potential of gene therapy. But one-time treatments will only be successful if they provide long-term benefit for patients.

For BioMarin Pharmaceuticals (BMRN), soon-to-be-released data could offer indications about just how durable its gene therapy against hemophilia A could be. In June, the Novato, Calif.-based biotech is expected to disclose an update from a clinical trial that has followed the treatment of patients for three years.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy